Which hedge funds own ARRYEUR? ARRAY BIOPHARMA INC, Q2 2026 13F holders
0 tracked hedge funds disclosed a position in ARRYEUR (ARRAY BIOPHARMA INC) in their Q2 2026 13F filings, worth $0 in total.
- 0
- Holders
- 0
- New this quarter
- 0
- Exited this quarter
- $0
- Combined value
- –
- Share of managers holding
Holders, Q2 2026
Ownership over time
By quarter
| Quarter | Holders | Managers filing | Share holding | Combined value |
|---|---|---|---|---|
| Q3 2019 | 0 | 60 | 0.0% | $0 |
| Q2 2019 | 6 | 60 | 10.0% | $670m |
| Q1 2019 | 4 | 60 | 6.7% | $252m |
| Q4 2018 | 3 | 60 | 5.0% | $203m |
| Q3 2018 | 2 | 59 | 3.4% | $112m |
| Q2 2018 | 4 | 59 | 6.8% | $121m |
| Q1 2018 | 5 | 59 | 8.5% | $75.4m |
| Q4 2017 | 3 | 59 | 5.1% | $82.4m |
| Q3 2017 | 3 | 56 | 5.4% | $113m |
| Q2 2017 | 3 | 56 | 5.4% | $29.0m |
| Q1 2017 | 1 | 56 | 1.8% | $11.4m |
| Q4 2016 | 1 | 56 | 1.8% | $13.8m |
| Q3 2016 | 2 | 52 | 3.8% | $3.8m |
| Q2 2016 | 1 | 52 | 1.9% | $62.0k |
| Q1 2016 | 1 | 52 | 1.9% | $6.4m |
| Q4 2015 | 3 | 52 | 5.8% | $18.0m |
| Q3 2015 | 2 | 52 | 3.8% | $4.3m |
| Q2 2015 | 2 | 52 | 3.8% | $6.8m |
| Q1 2015 | 2 | 52 | 3.8% | $17.8m |
| Q4 2014 | 1 | 52 | 1.9% | $4.3m |
| Q3 2014 | 2 | 49 | 4.1% | $5.1m |
| Q1 2014 | 0 | 47 | 0.0% | $0 |
| Q4 2013 | 1 | 47 | 2.1% | $1.8m |
| Q3 2013 | 1 | 45 | 2.2% | $3.6m |
| Q1 2013 | 0 | 39 | 0.0% | $0 |
| Q4 2012 | 1 | 40 | 2.5% | $97.0k |
Who discovered ARRYEUR first?
Earliest meaningful positions among the 10 tracked managers seen opening ARRYEUR since Q4 2012.
| RA Capital Management, L.P. | Q1 2015 | 1.1% | Exited by Q3 2015 | −2.2% |
| Farallon Capital Management, L.L.C. | Q1 2018 | 0.4% | Exited by Q3 2019 | +326% |
Stock since is the split-adjusted change in the quarter-end price, excluding dividends, from the first reported quarter: the price the 13F filings themselves imply (value ÷ shares), blank across any gap that cannot be accounted for. It describes the stock, not the return any manager earned.